Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

pembrolizumab 1osimertinib 1durvalumab 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Non Small Cell Lung Cancer × durvalumab × Clear all
NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

AstraZeneca

Phase 1 Active not recruiting
344 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡